| Literature DB >> 22474426 |
G Garruti1, F Giampetruzzi, M G Vita, F Pellegrini, P Lagioia, G Stefanelli, A Bellomo-Damato, F Giorgino.
Abstract
BACKGROUND: Type 2 diabetes (T2D) might occur within metabolic syndrome (MbS). One of the complications of T2D is an impaired (imp) cardiovascular autonomic function (CAF). AIMS: In subjects with T2D and age ≤ 55 years, the prevalence of impCAF and its relationship with BMI, waist, HbA(1c) values, MbS, hypertension, and family history of T2D and/or hypertension were analysed.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22474426 PMCID: PMC3312199 DOI: 10.1155/2012/615835
Source DB: PubMed Journal: Exp Diabetes Res ISSN: 1687-5214
Diagnostic criteria for the metabolic syndrome.
| Any 3 of the following conditions | ||
|
| ||
|
| ||
| According to NCEPIII* | ||
|
| ||
| Country/ethnic group | Sex | Waist in cm |
|
| ||
| Any | Male | ≥102 cm |
| Female | ≥88 cm | |
|
| ||
| Or according to IDF† | ||
|
| ||
| Country/ethnic group | Sex | Waist in cm |
|
| ||
| Europids | Male | ≥94 |
| Female | ≥80 | |
| South Asians, Chinese | Male | ≥90 |
| Female | ≥80 | |
| Japanese | Male | ≥85 |
| Female | ≥90 | |
|
| ||
| (2) Elevated triglyceridemia (≥150 mg/dL). | ||
| (3) Decreased HDL cholesterolemia (<40 mg/dL in males, <50 mg/ dL in females). | ||
| (4) Elevated arterial blood pressure (≥130/85 mmHg). | ||
| (5) Elevated fasting blood glucose (≥110 mg/dL or ≥100 mg/dL according to IDF†). | ||
*Adapted from the third report of the National Cholesterol Education Program (NCEPIII) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, ATP III). †International Diabetes Federetion.
Figure 1Distribution of different scores of impaired CAF in the cohort.
Figure 2Distribution of BMI classes in the cohort.
Figure 3Prevalence of metabolic syndrome in the cohort in the presence or in the absence of impaired CAF. Abbreviations: CAF+, presence of impaired CAF; MbS+, presence of Metabolic syndrome; MbS−, absence of metabolic syndrome. Notes. Sixty patients out of 180 had an impaired CAF.
Figure 4Distribution of different components of the metabolic syndrome in the female cohort in the presence or in the absence of impaired CAF. Abbreviations: CAF+: presence of impaired CAF; CAF−: absence of impaired CAF.
Figure 5Distribution of different components of the metabolic syndrome in the male cohort in the presence or in the absence of impaired CAF. Abbreviations: CAF+: presence of impaired CAF; CAF−: absence of impaired CAF.
Association between impaired CAF and anthropomentric and metabolic variables.
| BMI ≥ 24.9 Kg/m2 |
|
| Hypertension |
|
| Waist > 94/80 cm |
|
| Tryglycerides > 150 mg/dL |
|
| HbA1c≥ 7% |
|
| Protein intake ≤15%/day |
|
| Lipid intake > 30% |
|
| Metabolic syndrome |
|
BMI: Body mass index was calculated as Kg/m2.
| Variable | Age | BMI class | Family DM2 | Duration > 5 yrs | Fibers > 30 g/die | Glucides 55% | HbA1c > 7% | Family hypertension | Lipids > 30% | Metabolic syndrome | Proteins > 15% | Sex | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Category |
|
|
| ||||||||||||
|
| |||||||||||||||
| Univariate | IRR | 0.99 | 0.68 | 0.51 | 1.00 | 1.14 | 0.79 | 1.02 | 0.87 | 1.91 | 0.89 | 2.10 | 2.90 | 0.60 | 0.93 |
| IRR 95% CI | 0.96–1.03 | 0.41–1.14 | 0.26–0.98 | 1.00-1.00 | 0.62–2.13 | 0.49–1.29 | 0.60–1.72 | 0.37–2.04 | 1.18–3.11 | 0.55–1.44 | 1.23–3.59 | 1.49–5.66 | 0.35–1.01 | 0.58–1.51 | |
|
| 0.7451 | 0.1475 |
| — | 0.669 | 0.351 | 0.9554 | 0.7531 |
| 0.6265 |
|
|
| 0.7748 | |
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 1.45 | 2.32 | 1.00 | 1.18 | 0.71 | 1.44 | 0.71 | 2.02 | 0.92 | 1.93 | 2.53 | 0.65 | 0.93 |
| IRR 95% CI | 0.93–1.04 | 0.69–3.02 | 0.82–6.53 | 1.00-1.00 | 0.53–2.64 | 0.39–1.29 | 0.76–2.72 | 0.25–2.03 | 1.09–3.73 | 0.52–1.63 | 0.82–4.50 | 1.08–5.90 | 0.30–1.39 | 0.51–1.69 | |
|
| 0.4908 | 0.3265 | 0.1115 | — | 0.683 | 0.2609 | 0.2682 | 0.5197 |
| 0.7664 | 0.13 |
| 0.2649 | 0.802 | |
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 1.4 | 2.45 | 1.00 | 0.7 | 1.92 | 1.97 | 2.50 | 0.76 | 1.00 | ||||
| IRR 95% CI | 0.94–1.03 | 0.68–2.91 | 0.88–6.85 | 1.00-1.00 | 0.39–1.25 | 1.07–3.46 | 0.87–4.47 | 1.08–5.78 | 0.38–1.52 | 0.55–1.80 | |||||
|
| 0.5131 | 0.3614 |
| — | 0.2241 |
| 0.106 |
| 0.4357 | 0.9944 | |||||
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 0.72 | 1.95 | 1.47 | 1.88 | 0.85 | 1.08 | |||||||
| IRR 95% CI | 0.94–1.03 | 0.40–1.29 | 1.08–3.53 | 0.73–2.93 | 0.90–3.96 | 0.43–1.66 | 0.60–1.92 | ||||||||
|
| 0.5243 | 0.263 |
| 0.2775 |
| 0.6309 | 0.8003 | ||||||||
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 0.72 | 1.96 | 1.62 | 1.90 | 1.06 | ||||||||
| IRR 95% CI | 0.94–1.03 | 0.40–1.30 | 1.08–3.54 | 0.92–2.85 | 0.90–3.99 | 0.60–1.89 | |||||||||
|
| 0.5333 | 0.2797 |
|
|
| 0.8385 | |||||||||
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 1.77 | 1.60 | 2.08 | 0.97 | |||||||||
| IRR 95% CI | 0.93–1.03 | 0.99–3.15 | 0.91–2.80 | 0.99–4.34 | 0.55–1.70 | ||||||||||
|
| 0.3911 |
| 0.1021 |
| 0.9098 | ||||||||||
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 1.97 | 2.91 | 0.93 | ||||||||||
| IRR 95% CI | 0.94–1.02 | 1.20–3.24 | 1.48–5.71 | 0.57–1.52 | |||||||||||
|
| 0.3205 |
|
| 0.7838 | |||||||||||
|
| |||||||||||||||
| Multivariate | IRR | 0.98 | 1.96 | 2.91 | |||||||||||
| IRR 95% CI | 0.94–1.02 | 1.19–3.22 | 1.48–5.71 | ||||||||||||
|
| 0.3223 |
|
| ||||||||||||
|
| |||||||||||||||
| Multivariate | IRR | 1.87 | 2.82 | ||||||||||||
| IRR 95% CI | 1.15–3.04 | 1.44–5.51 | |||||||||||||
|
|
|
| |||||||||||||
Statistical analysis was performed with Poisson's model.
(a)
| Variable | Category | Number of positive CAF tests | All |
| |
|---|---|---|---|---|---|
| At least one | None | ||||
|
| 61 | 119 | 180 | ||
|
| |||||
| Age | 48.9 ± 5.3 | 48.5 ± 6.5 | 48.6 ± 6.1 | 0.9372 | |
|
| |||||
| BMI | 31.6 ± 7.3 | 28.0 ± 5.0 | 29.2 ± 6.1 | 0.0032 | |
|
| |||||
| BMI class | <25 | 10 (16.4) | 35 (29.4) | 45 (25.0) | 0.0227 |
| 25–30 | 21 (34.4) | 49 (41.2) | 70 (38.9) | ||
| ≥30 | 30 (49.2) | 35 (29.4) | 65 (36.1) | ||
|
| |||||
| Duration | 6.0 ± 5.9 | 6.4 ± 6.5 | 6.3 ± 6.3 | 0.9071 | |
|
| |||||
| Duration ≥5 years | Not assessed | 3 (·) | 5 (·) | 8 (·) | 0.4557 |
| No | 34 (58.6) | 60 (52.6) | 94 (54.7) | ||
| Yes | 24 (41.4) | 54 (47.4) | 78 (45.3) | ||
|
| |||||
| Family diabetes | No | 11 (18.0) | 23 (19.3) | 34 (18.9) | 0.8336 |
| Yes | 50 (82.0) | 96 (80.7) | 146 (81.1) | ||
|
| |||||
| Family hypertension | No | 38 (62.3) | 71 (59.7) | 109 (60.6) | 0.7324 |
| Yes | 23 (37.7) | 48 (40.3) | 71 (39.4) | ||
|
| |||||
| Fibers | 27.6 ± 4.2 | 27.8 ± 4.0 | 27.7 ± 4.1 | 0.9747 | |
|
| |||||
| HDL-cholesterol | 39.1 ± 10.1 | 42.5 ± 11.3 | 41.3 ± 11.0 | 0.0685 | |
|
| |||||
| HbA1c | 7.7 ± 1.4 | 7.3 ± 1.5 | 7.4 ± 1.5 | 0.0292 | |
|
| |||||
| HbA1c> 6.5% | Not assessed | 1 (·) | 0 (·) | 1 (·) | 0.0864 |
| No | 15 (25.0) | 45 (37.8) | 60 (33.5) | ||
| Yes | 45 (75.0) | 74 (62.2) | 119 (66.5) | ||
|
| |||||
| HbA1c> 7% | Not assessed | 1 (·) | 0 (·) | 1 (·) | 0.0299 |
| No | 25 (41.7) | 70 (58.8) | 95 (53.1) | ||
| Yes | 35 (58.3) | 49 (41.2) | 84 (46.9) | ||
|
| |||||
| Height | 1.6 ± 0.1 | 1.7 ± 0.1 | 1.7 ± 0.1 | 0.0429 | |
|
| |||||
| Fibers >30 g/diet | Not assessed | 13 (·) | 22 (·) | 35 (·) | 0.8568 |
| No | 26 (54.2) | 51 (52.6) | 77 (53.1) | ||
| Yes | 22 (45.8) | 46 (47.4) | 68 (46.9) | ||
|
| |||||
| Hypertension | No | 27 (44.3) | 78 (65.5) | 105 (58.3) | 0.0061 |
| Yes | 34 (55.7) | 41 (34.5) | 75 (41.7) | ||
|
| |||||
| Lipids >30% | Not assessed | 13 (·) | 22 (·) | 35 (·) | 0.0048 |
| No | 28 (58.3) | 78 (80.4) | 106 (73.1) | ||
| Yes | 20 (41.7) | 19 (19.6) | 39 (26.9) | ||
|
| |||||
| Metabolic syndrome | No | 8 (13.1) | 50 (42.0) | 58 (32.2) | <0.0001 |
| Yes | 53 (86.9) | 69 (58.0) | 122 (67.8) | ||
Data are expressed as mean ± SD or %. Two-sided P values refer to the Mann-Whitney U test for continuous variables and Pearson's χ 2 for categorical variables.
(b)
| Variable | Category | Number of positive CAF tests | All |
| |
| At least one | None | ||||
|
| |||||
| Metabolic syndrome score | 1 | 3 (4.9) | 13 (10.9) | 16 (8.9) | 0.0001 |
| 2 | 5 (8.2) | 37 (31.1) | 42 (23.3) | ||
| 3 | 18 (29.5) | 27 (22.7) | 45 (25.0) | ||
| 4 | 23 (37.7) | 34 (28.6) | 57 (31.7) | ||
| 5 | 12 (19.7) | 8 (6.7) | 20 (11.1) | ||
|
| |||||
| Proteins >15% | Not assessed | 13 (·) | 22 (·) | 35 (·) | 0.0838 |
| No | 24 (50.0) | 34 (35.1) | 58 (40.0) | ||
| Yes | 24 (50.0) | 63 (64.9) | 87 (60.0) | ||
| Glucides >55% | Not assessed | 13 (·) | 22 (·) | 35 (·) | 0.4146 |
| No | 6 (12.5) | 8 (8.2) | 14 (9.7) | ||
| Yes | 42 (87.5) | 89 (91.8) | 131 (90.3) | ||
|
| |||||
| Sex | Female | 23 (37.7) | 40 (33.6) | 63 (35.0) | 0.5859 |
| Male | 38 (62.3) | 79 (66.4) | 117 (65.0) | ||
|
| |||||
| Triglycerides | 167.3 ± 92.1 | 140.9 ± 95.8 | 149.9 ± 95.1 | 0.0089 | |
|
| |||||
| Waist circumference | 104.9 ± 17.9 | 97.8 ± 12.6 | 100.2 ± 15.0 | 0.0146 | |
|
| |||||
| Weight | 85.0 ± 21.3 | 78.1 ± 14.7 | 80.4 ± 17.5 | 0.0597 | |
Data are expressed as mean ± SD or %. Two-sided P values refer to the Mann-Whitney U test for continuous variables and Pearson's χ 2 for categorical variables.
(c)
| Antidiabetic therapy | Sex | Patients/total |
|---|---|---|
| Diet alone | Male | 34/117 |
| Female | 17/63 | |
| Diet + metformin | Male | 26/117 |
| Female | 25/63 | |
| Diet + sulphonylureas or glinides | Male | 15/117 |
| Female | 3/63 | |
| Diet + metformin+ | Male | 27/117 |
| sulphonylureas or glinides | Female | 8/63 |
| Diet + insulin (basal/bolus) | Male | 6/117 |
| Female | 6/63 |
Notes. (1) The remaining 4 female subjects out of 63 were treated either with Insulin (basal/bolus) plus metformin or with insulin (basal/bolus) plus sulphonylureas or glinides plus metformin).
(2) The remaining 9 male subjects out of 117 were treated either with insulin basal plus glitazones and metformin or with insulin basal plus sulphonylurea and metformin.